Here, we identified a combined model of two lncRNAs (PVT1 and C5orf66-AS1) with an AUC of 0.972, which was higher than that of either PVTI (0.943) or C5orf66-AS1 (0.853) alone, indicating a more powerful ability to distinguish between patients with GC and healthy controls, especially for advanced GC patients. This evidence concerns the gene PVT1 and gastric cancer.